Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.55 |
| ▸ | NPY2R | P49146 | 6/20 | 0.53 |
| ▸ | NPY4R | P50391 | 6/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.53 |
| ▸ | NPY1R | P25929 | 4/20 | 0.53 |
| ▸ | CALCR | P30988 | 4/20 | 0.52 |
| ▸ | GLP1R | P43220 | 1/20 | 0.52 |
| ▸ | GCGR | P47871 | 1/20 | 0.52 |
| ▸ | GIPR | P48546 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567693 | 0.88 | GLP1R (0.55) | OPRD1CALCRGLP1RGCGRGIPR | |
| SCHEMBL30399259 | 0.86 | OPRD1 (0.52) | OPRD1CALCR | |
| SCHEMBL31656525 | 0.83 | GLP1R (0.56) | OPRD1CALCRGLP1RGIPR | |
| SCHEMBL29380684 | 0.83 | OPRD1 (0.55) | OPRD1 | |
| SCHEMBL29380135 | 0.83 | OPRD1 (0.59) | OPRD1 | |
| SCHEMBL29380030 | 0.83 | OPRD1 (0.55) | OPRD1 | |
| SCHEMBL29392582 | 0.83 | OPRD1 (0.55) | OPRD1 | |
| SCHEMBL29565233 | 0.83 | OPRD1 (0.55) | OPRD1 | |
| SCHEMBL29377127 | 0.83 | OPRD1 (0.55) | OPRD1 | |
| SCHEMBL30233341 | 0.83 | NPY1R (0.57) | OPRD1NPY2RNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277841-A2 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-22 | — | — | US | disclosed |
| US-20240024473-A1 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2024-01-25 | — | — | US | disclosed |
| CN-116601290-A | Human chimeric antigen receptor neutrophils, compositions, kits and methods of use | 普渡研究基金会 | 2023-08-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277841-A2 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PBK, KIT, MYD88 | OPRD1 3799/4885NPY2R 3831/4885NPY4R 3873/4885 |
| US-20240024473-A1 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PBK, KIT, MYD88 | OPRD1 3799/4885NPY2R 3831/4885NPY4R 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.